Momenta Pharmaceuticals Inc.'s surprising good fortune with the FDA's nod last week for the company's generic Lovenox sent shares skyrocketing 82 percent and capped five years of exchanges between the regulatory agency and Momenta with partner Sandoz, the generic unit of Basel, Switzerland-based Novartis AG. It also may have sent an ominous signal to Teva Pharmaceuticals Inc.

Targacept Inc.'s partner AstraZeneca plc last week talked up TC-5214, the adjunctive compound for major depressive disorder that just entered Phase III trials, giving nervous investors hope in the pharma giant, which will see the patent expire on Seroquel IR (quetiapine) in March 2012.